| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jan Torleif Pedersen, Einar M Sigurdsso. Tau immunotherapy for Alzheimer's disease. Trends in molecular medicine. vol 21. issue 6. 2016-03-01. PMID:25846560. |
targeting pathological tau protein in alzheimer's disease (ad) and related tauopathies has shown great potential in animal models. |
2016-03-01 |
2023-08-13 |
Not clear |
| Stefano Sens. Metal homeostasis in dementia. Free radical biology & medicine. vol 75 Suppl 1. 2016-03-01. PMID:26461423. |
however, alzheimer's disease-related neurodegeneration, deregulation of brain levels of ca(2) and zn(2) is instrumental in promoting amyloid-β (aβ) dysmetabolism and tau phosphorylation as well as interference with additional pathogenic factors like energy production failure, hyperexcitabilty, excitotoxicity, and oxidative stress. |
2016-03-01 |
2023-08-13 |
Not clear |
| Julia Fernández-Montoya, Mar Pére. Cathepsin D in a murine model of frontotemporal dementia with Parkinsonism-linked to chromosome 17. Journal of Alzheimer's disease : JAD. vol 45. issue 1. 2016-02-29. PMID:25428250. |
tauopathies, such as alzheimer's disease (ad) and frontotemporal dementia with parkinsonism linked to chromosome 17 (ftdp-17), are characterized by tau accumulation. |
2016-02-29 |
2023-08-13 |
mouse |
| Yunpeng Huang, Zhihao Wu, Bing Zho. hSOD1 promotes tau phosphorylation and toxicity in the Drosophila model. Journal of Alzheimer's disease : JAD. vol 45. issue 1. 2016-02-29. PMID:25524953. |
tau hyperphosphorylation has been found in several neurodegenerative diseases such as alzheimer's disease (ad), down syndrome, and amyotrophic lateral sclerosis (als). |
2016-02-29 |
2023-08-13 |
drosophila_melanogaster |
| Shahzad S Khan, George S Bloo. Tau: The Center of a Signaling Nexus in Alzheimer's Disease. Frontiers in neuroscience. vol 10. 2016-02-23. PMID:26903798. |
tau: the center of a signaling nexus in alzheimer's disease. |
2016-02-23 |
2023-08-13 |
Not clear |
| Shahzad S Khan, George S Bloo. Tau: The Center of a Signaling Nexus in Alzheimer's Disease. Frontiers in neuroscience. vol 10. 2016-02-23. PMID:26903798. |
tau is a microtubule-associated protein whose misfolding, hyper-phosphorylation, loss of normal function and toxic gain of function are linked to several neurodegenerative disorders, including alzheimer's disease (ad). |
2016-02-23 |
2023-08-13 |
Not clear |
| Gurdeep Marwarha, Othman Ghrib. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap? Experimental gerontology. vol 68. 2016-02-22. PMID:25261765. |
alzheimer's disease (ad), the most common form of dementia, is characterized histopathologically by the deposition of β-amyloid (aβ) plaques and neurofibrillary tangles-containing hyperphosphorylated tau protein in the brain. |
2016-02-22 |
2023-08-13 |
Not clear |
| Arlan Richardson, Veronica Galvan, Ai-Ling Lin, Salvatore Odd. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. Experimental gerontology. vol 68. 2016-02-22. PMID:25481271. |
rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of alzheimer's disease (ad-tg) as well as reduce aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. |
2016-02-22 |
2023-08-13 |
mouse |
| Edward Rockenstein, Cassia R Overk, Kiren Ubhi, Michael Mante, Christina Patrick, Anthony Adame, Alejandro Bisquert, Margarita Trejo-Morales, Brian Spencer, Eliezer Maslia. A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies. PloS one. vol 10. issue 3. 2016-02-22. PMID:25803611. |
while four-repeat (4r) tau is more abundant in corticobasal degeneration, progressive supranuclear palsy, and alzheimer's disease, three-repeat (3r) tau is the most abundant splice, in pick's disease. |
2016-02-22 |
2023-08-13 |
mouse |
| Prasanna Sivaprakasam, Xiaojun Han, Rita L Civiello, Swanee Jacutin-Porte, Kevin Kish, Matt Pokross, Hal A Lewis, Nazia Ahmed, Nicolas Szapiel, John A Newitt, Eric T Baldwin, Hong Xiao, Carol M Krause, Hyunsoo Park, Michelle Nophsker, Jonathan S Lippy, Catherine R Burton, David R Langley, John E Macor, Gene M Dubowchi. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core. Bioorganic & medicinal chemistry letters. vol 25. issue 9. 2016-02-19. PMID:25845281. |
when dosed orally in a transgenic mouse model of alzheimer's disease (ad), an exemplary compound showed significant lowering of tau phosphorylation at one of the gsk-3 phosphorylating sites, ser396. |
2016-02-19 |
2023-08-13 |
mouse |
| Oliver Reimann, Maria Glanz, Christian P R Hackenberge. Native chemical ligation between asparagine and valine: application and limitations for the synthesis of tri-phosphorylated C-terminal tau. Bioorganic & medicinal chemistry. vol 23. issue 12. 2016-02-19. PMID:25882528. |
we present the successful native chemical ligation (ncl) at an asn-val site employing β-mercaptovaline and subsequent desulfurization in the synthesis of native phosphorylated c-terminal tau, relevant for alzheimer's disease related research. |
2016-02-19 |
2023-08-13 |
Not clear |
| V Corsetti, F Florenzano, A Atlante, A Bobba, M T Ciotti, F Natale, F Della Valle, A Borreca, A Manca, G Meli, C Ferraina, M Feligioni, S D'Aguanno, R Bussani, M Ammassari-Teule, V Nicolin, P Calissano, G Amador. NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease. Human molecular genetics. vol 24. issue 11. 2016-02-16. PMID:25687137. |
nh2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of parkin and uchl-1: implications in alzheimer's disease. |
2016-02-16 |
2023-08-13 |
human |
| Ming Ye, Dai Zhou, Youxin Zhou, Chunming Su. Parkinson's disease-associated PINK1 G309D mutation increases abnormal phosphorylation of Tau. IUBMB life. vol 67. issue 4. 2016-02-16. PMID:25899925. |
multiple lines of evidence have demonstrated that hyperphosphorylated tau is associated with alzheimer's disease and parkinson's disease (pd). |
2016-02-16 |
2023-08-13 |
Not clear |
| Jerry B Hunt, Kevin R Nash, Devon Placides, Peter Moran, Maj-Linda B Selenica, Firas Abuqalbeen, Kevin Ratnasamy, Nina Slouha, Santiago Rodriguez-Ospina, Miloni Savlia, Yashobha Ranaweera, Patrick Reid, Chad A Dickey, Rodrigo Uricia, Clement G Y Yang, Leslie A Sandusky, Marcia N Gordon, Dave Morgan, Daniel C Le. Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 35. issue 44. 2016-02-12. PMID:26538654. |
tau accumulation remains one of the closest correlates of neuronal loss in alzheimer's disease. |
2016-02-12 |
2023-08-13 |
mouse |
| Neha S Gandhi, Isabelle Landrieu, Cillian Byrne, Predrag Kukic, Laziza Amniai, François-Xavier Cantrelle, Jean-Michel Wieruszeski, Ricardo L Mancera, Yves Jacquot, Guy Lippen. A Phosphorylation-Induced Turn Defines the Alzheimer's Disease AT8 Antibody Epitope on the Tau Protein. Angewandte Chemie (International ed. in English). vol 54. issue 23. 2016-02-11. PMID:25881502. |
a phosphorylation-induced turn defines the alzheimer's disease at8 antibody epitope on the tau protein. |
2016-02-11 |
2023-08-13 |
Not clear |
| R Scott Turner, Ronald G Thomas, Suzanne Craft, Christopher H van Dyck, Jacobo Mintzer, Brigid A Reynolds, James B Brewer, Robert A Rissman, Rema Raman, Paul S Aise. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. vol 85. issue 16. 2016-02-11. PMID:26362286. |
a randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate alzheimer disease (ad) examined its safety and tolerability and effects on biomarker (plasma aβ40 and aβ42, csf aβ40, aβ42, tau, and phospho-tau 181) and volumetric mri outcomes (primary outcomes) and clinical outcomes (secondary outcomes). |
2016-02-11 |
2023-08-13 |
Not clear |
| Muneaki Takahashi, Haruka Miyata, Fuyuki Kametani, Takashi Nonaka, Haruhiko Akiyama, Shin-ichi Hisanaga, Masato Hasegaw. Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau. Acta neuropathologica. vol 129. issue 6. 2016-02-10. PMID:25869641. |
alzheimer's disease (ad) is characterized by extracellular amyloid β (aβ) deposition and intracellular tau aggregation. |
2016-02-10 |
2023-08-13 |
Not clear |
| C Ising, M Stanley, D M Holtzma. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Clinical pharmacology and therapeutics. vol 98. issue 5. 2016-02-10. PMID:26250900. |
alzheimer disease (ad) is the most common cause of dementia and is characterized by the aggregation and accumulation of two proteins in the brain, amyloid-β (aβ) and tau. |
2016-02-10 |
2023-08-13 |
Not clear |
| Juan Deng, Ahsan Habib, Demian F Obregon, Steven W Barger, Brian Giunta, Yan-Jiang Wang, Huayan Hou, Darrell Sawmiller, Jun Ta. Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3β signaling pathway. Journal of neurochemistry. vol 135. issue 3. 2016-02-10. PMID:26342176. |
because inhibition of bace1 decreases glycogen synthase kinase 3 beta (gsk3β)-mediated alzheimer's disease (ad)-like tau phosphorylation in ad patient-derived neurons, we determined whether sappα also reduces gsk3β-mediated tau phosphorylation. |
2016-02-10 |
2023-08-13 |
mouse |
| Mariangela Iovino, Sylvia Agathou, Ana González-Rueda, Martin Del Castillo Velasco-Herrera, Barbara Borroni, Antonella Alberici, Timothy Lynch, Sean O'Dowd, Imbisaat Geti, Daniel Gaffney, Ludovic Vallier, Ole Paulsen, Ragnhildur Thóra Káradóttir, Maria Grazia Spillantin. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain : a journal of neurology. vol 138. issue Pt 11. 2016-02-09. PMID:26220942. |
tauopathies, such as alzheimer's disease, some cases of frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy, are characterized by aggregates of the microtubule-associated protein tau, which are linked to neuronal death and disease development and can be caused by mutations in the mapt gene. |
2016-02-09 |
2023-08-13 |
human |